RxDoctor Payments Data

Ernest Podrasky, MD

Cardiovascular Disease · Exeter, NHNPI 1376502823

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $3,148 of the $4,586 with a category attached, or 68.6%. Abbott accounts for 81.2% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $1,796 and has fallen 55.9% since, to $792 in 2025.

$4,586in general payments, 2019–2025

Across 44 payments — averaging $104.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Medtronic$458
  • Abiomed$149
  • Elutia, Inc.$148
  • Atricure, Inc.$107

What the payments were for

  • Travel & lodging$3,14869%
  • Food & beverage$1,43831%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott34$3,725
Medtronic(2 entities)6$458
Abiomed2$149
Elutia, Inc.1$148
Atricure, Inc.1$107

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,586 in reported general payments places this provider in the 75th percentile of 112 cardiovascular disease providers in New Hampshire.

See all cardiovascular disease providers in New Hampshire

Medicare billing

Part B allowed, 2024
$172,069
Medicare patients
1,360
Services billed
3,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban487$534,572
VyndamaxTafamidis13$458,587
XareltoRivaroxaban171$222,042
EntrestoSacubitril/Valsartan39$47,338
BrilintaTicagrelor41$31,662
Repatha SureclickEvolocumab27$20,313
FarxigaDapagliflozin Propanediol20$14,989
Dabigatran EtexilateDabigatran Etexilate Mesylate19$5,106
Metoprolol Succinate308$4,973
Atorvastatin Calcium270$2,823
Ezetimibe59$2,283
Diltiazem 24hr Er (Cd)Diltiazem Hcl76$2,167
Rosuvastatin Calcium177$2,083
Warfarin Sodium133$1,914
Carvedilol173$1,555

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Exeter

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →